Efficacy and safety of olodaterol once daily delivered via Respimat® in patients with GOLD 2-4 COPD: results from two replicate 48-week studies. [electronic resource]
Producer: 20150224Description: 629-45 p. digitalISSN:- 1178-2005
- Administration, Inhalation
- Adrenergic beta-2 Receptor Agonists -- administration & dosage
- Aged
- Area Under Curve
- Asia
- Australia
- Benzoxazines -- administration & dosage
- Bronchodilator Agents -- administration & dosage
- Double-Blind Method
- Equipment Design
- Female
- Forced Expiratory Volume
- Germany
- Humans
- Lung -- drug effects
- Male
- Middle Aged
- Nebulizers and Vaporizers
- New Zealand
- Predictive Value of Tests
- Pulmonary Disease, Chronic Obstructive -- diagnosis
- Severity of Illness Index
- Time Factors
- Treatment Outcome
- United States
No physical items for this record
Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial
There are no comments on this title.
Log in to your account to post a comment.